MEA Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029

Middle East and Africa leber congenital amaurosis market is projected to register a CAGR of 2.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
 

Market Segmentation: 
Middle East and Africa Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East and Africa leber congenital amaurosis market are:

• Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases
 

• Increase in pipeline products and clinical trials
 

Market Players:

The key market players for Middle East and Africa leber congenital amaurosis market are listed below:

• Spark Therapeutics, Inc.
• LKC Technologies
• CENTOGENE N.V.
• Optos, Metrovision
• Blue Print Genetics Oy (A Subsidiary of Quest Diagnostics)
• CD Genomics
• ProQR Therapeutics
• OCUGEN, INC.
• MeiraGTx Limited
• Coave Therapeutics
• IVERIC bio, Inc.
• Atsena Therapeutics
• Editas Medicine
• Eluminex Biosciences
• Okuvision
• Astellas Pharma Inc.
• Allergan, agtc 
• Gyroscope Therapeutics Limited 
• SparingVision 
• Kubota Pharmaceutical Holdings Co. Ltd.
• REGENXBIO Inc.